Fibrosis in chronic rejection of human liver allografts: Expression patterns of transforming growth factor-TGFβ1 and TGF-β3

Transplantation

Volumn 62, Issue 12, 1996, Pages 1776-1783

  Demirci, Gülcin ^a   Nashan, Björn ^a   Pichlmayr, Rudolf ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ALLOGRAFT; CONFERENCE PAPER; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ACTINS; CELL COUNT; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MACROPHAGES; MUSCLE, SMOOTH; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030471596     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199612270-00016     Document Type: Article

References (71)

1. Wiesner RH, Ludwig J, Krom RAF, Hay JE, van Hoek B. Hepatic allograft rejection: new developments in terminology, diagnosis, prevention, and treatment. Mayo Clin Proc 1993; 68: 69.
2. Shaw BW, Gordon RD, Iwatsuki S, Starzl TE. Retransplantation of the liver. Semin Liver Dis 1985; 5: 394.
3. Bäckman L, Gibbs J, Levy M, et al. Causes of late graft loss after liver transplantation. Transplantation 1993; 55: 1078.
4. Wiesner RH, Ludwig J, van Hoek B, Krom RAF. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology 1991; 14: 721.
5. Van Hoek B, Wiesner RH, Krom RAF, Ludwig J, Moore SB. Severe ductopenic rejection following liver transplantation: incidence, time of onset, risk factors, treatment, and outcome. Semin Liver Dis 1992; 12: 41.
6. Ludwig J, Wiesner RH, Batts KP, Perkins JD, Krom RAF. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987; 7: 476.
7. Freese DK, Snover DC, Sharp HL, Gross CR, Savick SK, Payne WD. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology 1991; 13: 882.
8. Tilney NL, Whitley WD, Diamond JR, Kupiec-Weglinski JW, Adams DH. Chronic rejection - an undefined conundrum. Transplantation 1991; 52: 389.
9. International Working Party. Terminology for hepatic allograft rejection. Hepatology 1995; 22: 648.
10. Vierling JM, Fennell RH. Histopathology of early and late human hepatic allograft rejection: evidence of progressive destruction of interlobular bile ducts. Hepatology 1985; 5: 1076.
11. Grond J, Gouw ASH, Poppema S, Sloof MJH, Gips CH. Chronic rejection in liver transplants: a histopathologic analysis of failed grafts and antecedent serial biopsies. Transplant Proc 1986; 18: 128.
12. Hubscher S, Neuberger J. Chronic rejection of the liver allograft. In: Neuberger J, Adams D, eds. Immunology of liver transplantation. Oxford, UK: Oxford University Press, Inc., 1993: 216.
13. Adams DH, Neuberger JM. Patterns of graft rejection following liver transplantation. J Hepatol 1990; 10: 113.
14. Demetris AJ, Qian S, Sun H, Fung JJ. Liver allograft rejection: an overview of morphologic findings. Am J Surg Pathol 1990; 14 (suppl 1): 49.
15. Ludwig J, Gross JB, Perkins JD, Moore SB. Persistent centrilobular necroses in hepatic allografts. Hum Pathol 1990; 21: 656.
16. Klintmalm GBG, Nery JR, Husberg BS, Gonwa TA, Tillery GW. Rejection in liver transplantation. Hepatology 1989; 10: 978.
17. Kemnitz J, Gubernatis G, Bunzendahl H, Ringe B, Pichlmayr R, Georgii A. Criteria for the histopathological classification of liver allograft rejection and their clinical relevance. Transplant Proc 1989; 21: 2208.
18. Ramadori G. The stellate cell (Ito-cell, fat-storing cell, lipocyte, perisinusoidal cell) of the liver. Virchows Arch B Cell Pathol 1991; 61: 147.
19. Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828.
20. Gressner AM, Bachem MG. Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis. Semin Liver Dis 1990; 10: 30.
21. Milani S, Herbst H, Schuppan D, Grappone C, Heinrichs OE. Cellular sources of extracellular matrix proteins in normal and fibrotic liver. Studies of gene expression by in situ hybridization. J Hepatol 1995; 22 (suppl 2): 71.
22. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 1985; 82: 8681.
23. Tsutsumi M, Takada A, Takase S, Ooshima A. Connective tissue components in cultured parenchymal and nonparenchymal cells of rat liver. Immunohistochemical studies. Lab Invest 1988; 58: 88.
24. Clement B, Grimaud JA, Campion JP, Deugnier Y, Guillouzo A. Cell types involved in collagen and fibronectin production in normal and fibrotic human liver. Hepatology 1986; 6: 225.
25. Milani S, Grappone C, Pellegrini G, et al. Undulin RNA and protein expression in normal and fibrotic human liver. Hepatology 1994; 20: 908.
26. Van Eyken P, Sciot R, Desmet VJ. Expression of the novel ECM component tenascin in normal and diseased human liver. An immunohistochemical study. J Hepatol 1990; 11: 43.
27. Johnson SJ, Hines JE, Burt AD. Immunolocalization of proliferating perisinusoidal cells in rat liver. Histochem J 1992; 24: 67.
28. Geerts A, Lazou JM, De Bleser P, Wisse E. Tissue distribution, quantitation and proliferation kinetics of fat-storing cells in carbon tetrachloride-injured rat liver. Hepatology 1991; 13: 1193.
29. Hines JE, Johnson SJ, Burt AD. In vivo responses of macrophages and perisinusoidal cells to cholestatic liver injury. Am J Pathol 1993; 142: 511.
30. Enzan H, Himeno H, Iwamura S, et al. Immunohistochemical identification of Ito cells and their myofibroblastic transformation in adult human liver. Virchows Arch A 1994; 424: 249.
31. Ramadori G, Veit T, Schwögler S, et al. Expression of the gene of the α-smooth muscle-actin isoform in rat liver and in rat fat-storing cells. Virchows Arch B Cell Pathol Incl Mol Pathol 1990; 59: 349.
32. Yamaoka K, Nouchi T, Marumo F, Sato C. α-Smooth-muscle actin expression in normal and fibrotic human livers. Dig Dis Sci 1988; 38: 1473.
33. Tanaka Y, Nouchi T, Yamane M, et al. Phenotypic modulation in lipocytes in experimental liver fibrosis. J Pathol 1991; 164: 273.
34. Nouchi T, Tanaka Y, Tsukada T, Sato C, Marumo F. Appearance of α-smooth muscle-actin-positive cells in hepatic fibrosis. Liver 1991; 11: 100.
35. Rockey DC, Boyles JK, Gabbiani G, Friedman SL. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 1992; 24: 193.
36. Geerts A, Schellinck P, Bouwens L, Wisse E. Cell population kinetics of Kupffer cells during the onset of fibrosis in rat liver by carbon tetrachloride administration. J Hepatol 1988; 6: 50.
37. Shiratori Y, Geerts A, Ichida T, Kawase T, Wisse E. Kupffer cells from CCL4-induced fibrotic livers stimulate proliferation of fat-storing cells. J Hepatol 1986; 3: 294.
38. Zerbe O, Gressner AM. Proliferation of fat-storing cells is stimulated by secretions of Kupffer cells from normal and injured liver. Exp Mol Pathol 1988; 49: 87.
39. Friedman SL, Arthur MJP. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. J Clin Invest 1989; 84: 1780.
40. Matsuoka M, Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor β: implication for a pathogenic role in alcoholic liver fibrogenesis. Hepatology 1990; 11: 599.
41. Meyer DH, Bachem MG, Gressner AM. Modulation of hepatic lipocyte proteoglycan synthesis and proliferation by Kupffer cell-derived transforming growth factors type β1 and type α. Biochem Biophys Res Commun 1990; 171: 1122.
42. Win KM, Charlotte F, Mallat A, et al. Mitogenic effect of transforming growth factor-β1 on human Ito cells in culture: evidence for mediation by endogenous platelet-derived growth factor. Hepatology 1993; 18: 137.
43. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 1286.
44. Bachem MG, Sell KM, Melchior R, Kropf J, Eller T, Gressner AM. TNF-α and TGF-β1 stimulate fibronectin synthesis and the transdifferentiation of fat-storing cells in the rat liver into myofibroblasts. Virchows Arch B Cell Pathol Incl Mol Pathol 1993; 63: 123.
45. Blazejewski S, Preaux AM, Mallat A, et al. Human myofibroblastlike cells obtained by outgrowth are representative of the fibrogenic cells in the liver. Hepatology 1995; 22: 788.
46. Casini A, Pinzani M, Milani S, et al. Regulation of extracellular matrix synthesis by transforming growth factor-β1 in human fat-storing cells. Gastroenterology 1993; 105: 245.
47. Casini A, Geni E, Salzano R, et al. Regulation of undulin synthesis and gene expression in human fat storing cells by acetaldehyde and transforming growth factor-β1: comparison with fibronectin. Biochem Biophys Res Commun 1994; 199; 1019.
48. Nakatsukasa H, Nagy P, Evarts EP, Hsia CC, Marsden E, Thorgeirsson SS. Cellular distribution of transforming growth factor-β1 and procollagen types I, III and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest 1990; 85: 1833.
49. Castilla A, Prieto J, Fausto N. Transforming growth factors β1 and α in chronic liver disease. Effects of interferon alpha therapy. N Engl J Med 1991; 324: 933.
50. Nagy P, Schaff Z, Lapis K. Immunohistochemical detection of transforming growth factor-β1 in fibrotic liver diseases. Hepatology 1991; 14: 269.
51. Cox DA. Transforming growth factor-beta 3. Cell Biol Int 1995; 19: 357.
52. Boumediene K, Vivien D, Macro M, Bogdanowicz P, Lebrun E, Pujol JP. Modulation of rabbit articular chondrocyte (RAC) proliferation by TGF-β isoforms. Cell Prolif 1995; 28: 221.
53. Huang JX, Potts JD, Vincent EB, Weeks DL, Runyan RB. Mechanisms of cell transformation in the embryonic heart. Ann NY Acad Sci 1995; 752: 317.
54. Santana A, Saxena B, Noble NA, Gold LI, Marshall BC. Increased expression of transforming growth factor β isoforms (β1, β2, β3) in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 1995; 13: 34.
55. Zwadlo G, Bröcker EB, von Bassewitz DB, Feige U, Sorg C. A monoclonal antibody to a differentiation antigen present on mature human macrophages and absent from monocytes. J Immunol 1985; 134: 1487.
56. Zwadlo G, Schlegel R, Sorg C. A monoclonal antibody to a subset of human monocytes found only in the peripheral blood and inflammatory tissues. J Immunol 1986; 137: 512.
57. Steinhoff G, Wonigeit K, Pichlmayr R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation 1988; 45: 394.
58. Hoffmann MW, Wonigeit K, Steinhoff G, Herzbeck H, Flad HD, Pichlmayr R. Production of cytokines (TNF-alpha, IL-1-beta) and endothelial cell activation in human liver allograft rejection. Transplantation 1993; 55: 329.
59. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation 1993; 56: 69.
60. Gubernatis G, Kemnitz J, Tusch G, Pichlmayr R. HLA compatibility and different features of liver allograft rejection. Transpl Int 1988; 1: 155.
61. Lowry RP, Takeuchi T, Cremisi H, Konieczny B, Someren A. Chronic rejection of organ allografts may arise from injuries sustained in recurring foci of acute rejection that resolve spontaneously. Transplant Proc 1993; 25: 2103.
62. Arnold CA, Portmann BC, O'Grady JG, Naoumov NV, Alexander GJM, Williams R. Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology 1992; 16: 285.
63. Bronsther O, Manez R, Kusne S, et al. Posttransplant B, non-A non-B, and cytomegalovirus hepatitis increase the risk of developing chronic rejection after liver transplantation. Transplant Proc 1995; 27: 1206.
64. Mathew J, Hines JE, Toole K, Johnson SJ, James OFW, Burt AD. Quantitative analysis of macrophages and perisinusoidal cells in primary biliary biliary cirrhosis. Histopathology 1994; 25: 65.
65. Hayashi M, Martinez OM, Garcia-Kennedy R, So S, Esquivel CO, Krams SM. Expression of cytokines and immune mediators during chronic liver allograft rejection. Transplantation 1995; 60: 1533.
66. Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 1990; 6: 597.
67. Bissell DM, Wang SS, Jarnagin WR, Roll FR. Cell specific expression of transforming growth factor-β in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 1995; 96: 447.
68. Chiquet-Ehrisman R. What distinguishes tenascin from fibronectin? FASEB J 1990; 4: 2598.
69. Kim SJ, Denhez F, Kim KY, Holt JT, Sporn MB, Roberts AB. Activation of the second promoter of the transforming growth factor-β1 gene by transforming growth factor-β1 and phorbol ester occurs through the same target sequences. J Biol Chem 1989; 264: 19373.
70. Inagaki Y, Truter S, Greenwel P, et al. Regulation of the α2(I) collagen gene transcription in fat-storing cells derived from a cirrhotic liver. Hepatology 1995; 22: 573.
71. Gressner AM, Bachem MG. Molecular mechanisms of liver fibrogenesis - a homage to the role of activated fat-storing cells. Digestion 1995; 56: 335.